Article Sidebar

PDF
Date Published: 30/09/2022
Online Published: 30/09/2022
Abstract Views: 185
Views PDF: 49
DOI: https://doi.org/10.55046/vjrnm.48.772.2022
Issue
No. 48 (2022)
Section
Scientific research
How to Cite
Nguyen, T. K. D., Nguyen, K. T., Nguyen, M. T., Pham, D. T., & Nguyen, Q. T. (2022). EVALUATION OF 18 FLUORIN-FLUOROTHYMIDINE UPTAKE IN TUMOR-BEARING MICE. Vietnamese Journal of Radiology and Nuclear Medicine, 48, 70-75. https://doi.org/10.55046/vjrnm.48.772.2022

EVALUATION OF 18 FLUORIN-FLUOROTHYMIDINE UPTAKE IN TUMOR-BEARING MICE

Nguyen Thi Kim Dung1, Nguyen Khac That1, Nguyen Minh Thu2, Pham Dang Tung3, Nguyen Quóc Thang4
1 Department of Nuclear Medicine, Military Central Hospital 108
2 Diagnostic Imaging Center, Military Central Hospital 108
3 Faculty of Pharmacy, Phenikaa University
4 Vinmec Times City International General Hospital

Main Article Content

Abstract

PET (positron emission tomography) techniques and radiopharmaceutical tracers are becoming increasingly common. Since 1991, 3’-deoxy-3’-18Fluorine-Fluorothymidine (18F-FLT) has been studied as a PET tracer for tumor proliferation assessment. The purpose of this study was to assess tracer uptake (%ID/g) in tumor-bearing mice. Materials and methods: Two cell lines (4T1 and LLC) were inoculated into BALB/c mice. The radiotracer was then injected, and tumor resection and organ samples were performed at 20, 40, 60, 90 and 120 minutes later. A gamma-ray spectrometer was used to calculate uptake values. Results: The data show that the tumor’s %ID/g were 3,68 ± 0,29 and 5,30 ± 0,44 at 60-minute post-injection for the 4T1 and LLC tumors, respectively. In other organs, the high uptake was observed in the kidneys, spleen, and bone marrow, but a low level of tracer was seen in the brain.

Article Details

Keywords

3’-deoxy-3’-18Fluorine-Fluorothymidine, positron emission tomography, tumor-bearing mice

References

1. Pauwels, E.K., et al., Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol, 2000. 126(10): p. 549-59. https://doi.org/10.1007/PL00008465.
2. Mamede, M., et al., [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia, 2005. 7(4): p. 369-79. https://doi.org/10.1593/neo.04577.
3. Corrigan, A.J., P.J. Schleyer, and G.J. Cook, Pitfalls and Artifacts in the Use of PET/CT in Oncology Imaging. Semin Nucl Med, 2015. 45(6): p. 481-99. https://doi.org/10.1053/j.semnuclmed.2015.02.006.
4. Jadvar, H., Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol, 2012. 199(2): p. 278-91. https://doi.org/10.2214/ajr.12.8816.
5. Couturier, O., et al., [Is 3'-deoxy-3'- [18F] fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG?]. Bull Cancer, 2005. 92(9): p. 789-98. https://pubmed.ncbi.nlm.nih.gov/16203269.
6. Schwartz, J.L., et al., Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med, 2003. 44(12): p. 2027-32. https://pubmed.ncbi.nlm.nih.gov/14660729.
7. Chalkidou, A., et al., Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. Eur J Cancer, 2012. 48(18): p. 3499-513. https://doi.org/10.1016/j.ejca.2012.05.001.
8. Shen, G., et al., Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer: a meta-analysis. Acta Radiol, 2018. 59(2): p. 188-195. https://doi.org/10.1177/0284185117706609.
9. Shields, A.F., et al., Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med, 1998. 4(11): p. 1334-6. https://www.nature.com/articles/nm1198_1334.
10. McKinley, E.T., et al., Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. PLoS One, 2013. 8(3): p. e58938. https://doi.org/10.1371/journal.pone.0058938.
11. Fueger, B.J., et al., Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med, 2006. 47(6): p. 999-1006. https://pubmed.ncbi.nlm.nih.gov/16741310.
12. Apisarnthanarax, S., et al., Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res, 2006. 12(15): p. 4590-7. https://doi.org/10.1158/1078-0432.ccr-05-2720.
13. Bao, X., et al. Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging. Biomed Res Int, 2014. 2014: p. 218578. https://doi.org/10.1155/2014/218578.